Articles tagged with Breast Cancer
Researchers have discovered how CDK8 is activated in healthy humans and identified a new method for developing CDK8-specific inhibitors. The study suggests that targeting the 'MED12 activation helix' may be crucial for inhibiting CDK8 activity, which is often mutated in various cancers.
A study examined racial and ethnic differences in genetic testing frequency and results among diverse young breast cancer patients. The study found that less than half of the participants completed hereditary breast and ovarian cancer genetic testing, but the percentage increased over time.
Researchers developed a new method that combines genomic and proteomic analysis to provide more detailed insights into cancer biology, tumor type, and response to therapy. The study showed promise for future clinical application and highlights the potential for precision medicine.
Researchers found that protein AKAP8 inhibits breast cancer metastasis by interfering with proteins that promote metastatic behavior. AKAP8 also predicts metastatic breast cancer outcomes in patients and can inhibit progression in animal models.
Consuming natural yoghurt daily may lower breast cancer risk by displacing harmful bacteria with beneficial ones. Breastfeeding also reduces the risk, likely due to lactose fermenting bacteria occupying breast ducts.
A University of Massachusetts Amherst researcher is studying the effects of endocrine-disrupting chemicals on breast density in college-age women, a strong risk factor for breast cancer. High breast density has been linked to increased breast cancer risk in older women, and this study aims to shed light on the link in younger women.
Researchers have discovered a two-drug combo that can counter resistance to a promising new breast cancer therapy. The combination of neratinib and everolimus effectively blocks the growth of cancer cells with HER2 mutations, providing a novel treatment option for patients with these types of cancers.
Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy. PET/MRI imaging revealed differences in biomarkers between healthy contralateral breast tissue of patients with malignant and benign breast tumors.
Researchers developed a new compound that targets microRNA-21, a molecule linked to aggressive breast cancer, awakening its self-destruct system and killing cancer cells while leaving healthy cells unaffected. In mouse models, the compound showed promise in reducing breast cancer spread and decreasing invasiveness in other cancers.
Hyperpolarized 13C-Magnetic resonance imaging (HP 13C-MRI) reveals the conversion of pyruvate into lactate in breast cancer tumors, associated with higher tumor grades. The study suggests HP 13C-MRI as a noninvasive tool for characterizing and monitoring breast tumors.
Researchers have developed a new scanning technique using magnetized molecules to monitor breast cancer, detecting differences in tumor size, type, and grade. The scan reveals the 'topography' of tumors, providing detailed information on metabolism and identifying potential treatment options.
Researchers used imaging mass cytometry to analyze 35 protein biomarkers in breast cancer patients, identifying four subcategories of the disease with varying molecular profiles. This breakthrough has the potential to change clinical practice by enabling precision medicine and personalized treatment approaches.
Research links proton pump inhibitors to poorer concentration and memory in breast cancer patients. Cognitive problems reported by PPI users were 20-29% more severe than those in non-users. The study suggests an association between PPI use and cognitive decline in breast cancer survivors.
Researchers discover that hormone resistant ER+ breast cancers have a 'rewired' 3D structure of DNA, altering gene activation and silencing. This change may explain how cancer cells evade hormone therapy, offering a potential path for reversal using existing drugs.
Researchers discovered that restoring BMP4 activity blocks distant metastasis in multiple organs, including the lung and bone. High levels of BMP4 are associated with better patient outcomes.
Researchers developed a new nanoparticle drug formulation targeting specific receptors on cancer cells, dispersing chemotherapy drug paclitaxel evenly throughout tumors. The study found the 'DART' nanoparticles significantly increased median overall survival compared to Abraxane treatment in animal studies.
UMass Amherst researchers discovered that benzophenone-3 and propylparaben can cause DNA damage in breast cells with estrogen receptors, even at low concentrations. This finding suggests a new mechanism by which estrogens and xenoestrogens may promote breast cancer.
Researchers developed an integrated genomic approach to predict which lung cancer patients will respond to immunotherapy. They found a correlation between tumor mutational burden and tumor purity, and corrected TMB estimates improved prediction of overall survival.
Researchers developed an interactive health counselor to educate women about breast density, with participants showing increased knowledge and satisfaction. The prototype aims to empower women with accurate information throughout the breast cancer screening process.
A new study published in JAMA Oncology finds that lack of insurance coverage is a major cause of delayed breast cancer screening and treatment among minority women. The research highlights the need for adequate health insurance to reduce racial outcome disparities in breast cancer.
A new study shows that the 21-gene recurrence score test, commonly used to predict disease recurrence and chemotherapy benefit in breast cancer patients, may also help determine whether radiation therapy is necessary. Patients with intermediate or high scores are more likely to see their cancer return and benefit from radiation.
A new study suggests that state-mandated notifications on mammogram reports intended to inform women of the health risks related to breast density are not worded effectively, particularly for those with lower education levels.
The American Cancer Society's annual report on cancer rates and trends shows a steady 26-year decline in overall cancer mortality, with long-term drops in lung, colorectal, breast, and prostate cancers. Lung cancer death rates have dropped by 51% since 1990, with the most rapid progress in recent years.
A nationwide Danish study found that overweight and obesity were associated with a 12% higher risk of several common cancers. The study included 20,706 cancers among 313,321 adults diagnosed with overweight and obesity compared to expected cancers in the general population.
A new study found that US patients are less likely to undergo breast conserving therapy compared to European and Asian patients, with a higher rate of mastectomy. The study suggests that insurance coverage and costs may be factors influencing this difference.
A research team at UC Riverside has received a four-year NIH grant to investigate luminal B breast cancer and triple-negative breast cancer, with the goal of improving early detection and patient survival. The project aims to develop resources and training programs for diverse therapeutics researchers.
The study found significant tumor shrinkage in two out of three patients with salivary gland tumors treated with T-DM1. The benefit lasted for at least two years in one patient, suggesting a promising activity for this rare cancer type.
Researchers have developed new drug compounds that inhibit the activity of FOXM1, a transcription factor that regulates cell proliferation and development. The compounds suppress tumor growth in human cells and mouse models of several types of breast cancer.
A major international study has identified over 350 DNA 'errors' that increase breast cancer risk, providing the most detailed picture yet of how differences in our DNA put some women at greater risk. The researchers found that 191 genes are likely target genes for these variants.
Researchers have discovered a novel combination of antibodies that significantly enhances the effectiveness of cancer immunotherapy, particularly in 'cold' tumors. The combination stabilizes tumor blood vessels and strengthens the immune system, leading to improved tumor tissue destruction.
Researchers found that combining valproic acid and hydralazine reversed some aspects of breast cancer in offspring of high-risk mice, but increased risk in those not fed a high fat diet during pregnancy. The study suggests potential implications for breast cancer risk in humans, particularly related to prenatal exposure to certain chem...
A recent study found that obesity is a significant risk factor for cardiotoxicity in breast cancer patients treated with chemotherapy, particularly those receiving anthracyclines and trastuzumab. The study suggests that overweight and obese individuals may benefit from careful cardiac screening and follow-up during treatment.
A new study explores women's knowledge and perceptions of breast density and breast cancer screening across three states with varying notification laws. Women from all states had varying knowledge about their own breast density and breast density in general, and expressed a strong desire for more information.
Researchers at Penn Medicine used MRI scans to characterize tumor heterogeneity and predict 10-year breast cancer recurrence. High tumor heterogeneity was found to be a strong predictor of recurrence in patients with primary invasive breast cancer.
A new study led by Christine B. Ambrosone found that breast cancer patients taking antioxidants during chemotherapy had a 41% increased risk of disease recurrence and a similar but weaker risk of death. Patients using vitamin B12, iron, and omega-3 fatty acid supplements also showed poorer outcomes.
A phase 2 clinical trial has demonstrated an effective alternative to mastectomy for breast cancer patients experiencing recurrence after initial lumpectomy and whole-breast radiation. The treatment involved a second lumpectomy followed by partial breast reirradiation, resulting in long-term cancer control and low toxic side effects.
Researchers have identified a genetic signature associated with the degree of pathological angiogenesis in breast cancer tumors. The study combined gene expression profiles from public databases with analysis of retinopathy models to uncover key genes involved in pathological angiogenesis, providing a new tool for breast cancer treatment.
A national survey of women found that DBNs are not achieving their desired effects in reducing breast cancer awareness and screening. The study revealed greater anxiety and confusion among black women with higher incomes, while white women with higher incomes had more knowledge about breast density.
A new AI model developed by researchers can predict which women are at future risk of breast cancer with higher accuracy than existing models. The deep neural network-based approach has a lower false negative rate, indicating that it can identify women who would benefit from additional screening with MRI.
A large new study finds that sustained weight loss is associated with lower breast cancer risk in women over 50. Women who lost weight after age 50 and kept it off had a 13-26% lower risk of breast cancer compared to those whose weight remained stable.
A large US population-based analysis found that breast cancer survivors face significant non-cancer-related deaths, including heart diseases and Alzheimer's. Most deaths occurred within 10 years of diagnosis, with patients at higher risk for chronic liver disease and other conditions compared to the general population.
A retrospective study found that women with government insurance had lower survival rates, increased risk of dying, and were more likely to stop treatment early in breast cancer clinical trials. The study also did not find a significant association between neighborhood socioeconomic status and trial outcomes.
Researchers found that residual cancer burden index and classification are accurate and reliable tools to assess patient prognosis. The results suggest that continuous RCB index can predict risk of breast cancer recurrence across all four breast cancer subtypes.
Researchers found that women who used ibuprofen or naproxen had a 40% reduced breast cancer risk, while aspirin use offered no benefit. Young women with HER2-positive breast cancer may preserve fertility by choosing less intensive chemotherapy regimens.
A team of researchers from IU School of Medicine has discovered a way to predict the recurrence of triple negative breast cancer in women. They found that patients without circulating tumor DNA in their plasma had an 81% chance of being cancer-free after two years, compared to 56% for those with detectable levels.
The American College of Medical Genetics and Genomics recommends evaluating all breast cancer patients for hereditary predisposition. However, they caution that there is insufficient evidence to support genetic testing for BRCA1/2 or multi-gene panels in all breast cancer patients.
A recent NRG Oncology study found that breast-conserving treatment without surgery is not feasible based on the study's criteria. The study showed a negative predictive value of 77.5% for tumor bed biopsies, which falls short of the required threshold to support omitting surgery.
Breast cancer incidence rates are significantly higher in black men than white men, particularly for hormone receptor-positive subtypes. These racial differences have significant implications for patient outcomes and may be linked to genetic and non-genetic factors.
The NRG Oncology/NSABP B-42 trial found that extending letrozole therapy for five additional years improved disease-free survival in postmenopausal women with HR+ breast cancer. The study showed a 26% decrease in the risk of breast-cancer-free interval events and a 29% reduction in distant recurrence rates.
Researchers at Baylor College of Medicine classified over 500 cancers into 10 subtypes based on protein analysis, revealing novel molecular pathways and potential new players in cancer. Four subtypes were found to be linked to the tumor microenvironment, while three others were associated with previously unknown cellular components.
Researchers at Dartmouth's Norris Cotton Cancer Center found that breast cancer cells can take up large quantities of fat from the bloodstream through a novel mechanism called endocytosis of lipoproteins. This uptake provides a reliable source of energy for cancer cell proliferation.
Recent study suggests a modest association between radioiodine treatment for hyperthyroidism and increased risk of solid cancer, including breast cancer. The Society for Endocrinology and British Thyroid Association advise caution in interpreting the findings and highlight the need for further research.
The American College of Medical Genetics and Genomics recommends evaluating breast cancer patients for genetic testing based on existing clinical criteria. Genetic testing should include full gene sequencing and be conducted in a lab certified by the College of American Pathologists or Clinical Laboratory Improvement Amendments.
The IBIS-II study confirms anastrozole offers long term protection for women at high risk of developing breast cancer, with a 49% reduction in breast cancer incidence 12 years after stopping treatment. This is significantly higher than the 28% decrease in breast cancer recorded for women who take tamoxifen.
A phase III clinical trial shows tucatinib significantly improves survival rates in women with HER2+ breast cancer, especially those with brain metastases. The study found nearly tripled one-year progression-free survival and doubled two-year overall survivor compared to standard treatment.
Hyperactive FOXA1 signaling triggers genome-wide reprogramming in endocrine-resistant breast cancer cells, leading to enhanced resistance to treatment and metastatic behaviors. An inhibitor of HIF-2a reduces migration and invasion of these cells, providing a potential therapeutic strategy.
The trial showed that adding tucatinib to capecitabine and trastuzumab improved progression-free and overall survival in advanced HER2-positive breast cancer patients, regardless of whether they had brain metastasis. The treatment combination also increased the overall response rate compared to standard care.
Researchers at Hollings Cancer Center discovered that combining a polo-like kinase 1 inhibitor with a standard chemotherapeutic agent reduced TNBC tumor volume four times more effectively than the agent alone. The combination also reduces cancer stem cells, associated with metastasis.
A Japanese study of 63,232 patients with cancer and controls found a linear association between alcohol consumption and increased cancer risk. Those who drank two or fewer drinks per day had an elevated cancer risk regardless of how long they had consumed alcohol.
Researchers at The Mount Sinai Hospital have discovered a potential therapy, MS1943, that selectively degrades EZH2 protein in cancer cells. Effective against triple-negative breast cancer, it reduces EZH2 levels and kills cancer cells.